Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes
Pooled result · Fatal and nonfatal MIResult — go to the resultOdds ratio 0.92 95% CI 0.86–0.99Authors' conclusion
In high-risk patients with T2DM, GLP-1RAs were associated with a decrease in MI, especially the human-based and once-weekly GLP-1RAs. No benefit was seen for hospitalization for unstable angina or coronary revascularization. Further research is urgently needed to ascertain improvements in coronary events.
Study context
- Population
- Patients with T2D in studies with a cardiovascular endpoint
- Participants
- 64,236 patients9 studies
- Comparison
- GLP-1 RA vs placebo
- Outcome
- Major coronary events: MI, unstable angina and coronary revascularization
Pooled result
Fatal and nonfatal MI
Odds ratio
0.92
95% CI 0.86–0.99
P = 0.02
GLP-1RAsvs Placebo
OR 0.92 (95% CI 0.86–0.99); P = 0.02
As reported in the abstract
- Reduction in fatal and nonfatal myocardial infarction (MI)
- 8%
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Hospitalization for unstable anginaI2 = 21% | 1.11 (0.97–1.28) | P = 0.13 | |
| Coronary revascularizationI2 = 22% | 0.95 (0.89–1.02) | P = 0.15 | |
| 0.512Odds ratio (log scale) |
MI, human-based GLP-1RAs (subgroup)
- Reduction in MI
- 15%
MI, once-weekly GLP-1RAs (subgroup)
- Reduction in risk of MI
- 13%
Coronary revascularization, human-based GLP-1RAs (subgroup)
- Reduction in risk
- 11%
Original publication
Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes. Diabetes Obes Metab. Published 31 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →